Linda Chang

Title: Linda Chang: Innovator in Anti-Type I Interferon Receptor Therapies

Introduction

Linda Chang is a prominent inventor based in Gaithersburg, MD (US). She has made significant contributions to the field of medicine, particularly in the treatment of type I interferon-mediated diseases. Her innovative work has led to the development of a patented method that enhances therapeutic approaches for patients suffering from these conditions.

Latest Patents

Linda Chang holds a patent for "Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies." This patent outlines methods for treating subjects with type I IFN-mediated diseases or disorders through the administration of a fixed dose of an anti-interferon alpha receptor antibody. The disclosure also includes methods for suppressing a type I interferon gene signature in patients. Furthermore, it provides techniques for prognosing or monitoring disease progression, predicting dosage regimens, identifying candidate therapeutic agents, and designating personalized therapies.

Career Highlights

Linda Chang is currently associated with MedImmune Limited, where she continues to advance her research and development efforts. Her work has been instrumental in shaping new treatment paradigms for complex diseases, showcasing her dedication to improving patient outcomes.

Collaborations

Linda collaborates with esteemed colleagues such as Brandon Higgs and Yihong Yao. Their combined expertise fosters an environment of innovation and progress in the field of medical research.

Conclusion

Linda Chang's contributions to the medical field through her patented innovations demonstrate her commitment to advancing healthcare solutions. Her work not only addresses critical health challenges but also paves the way for future research and development in therapeutic strategies.